Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccine

Journal of Clinical Oncology

Volumn 22, Issue 10, 2004, Pages 1916-1925

  Disis, Mary L ^a   Schiffman, Kathy ^a   Guthrie, Katherine ^a   Salazar, Lupe G ^a   Knutson, Keith L ^a   Goodell, Vivian ^a   Dela Rosa, Corazon ^a   Cheever, Martin A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 INTRACELLULAR DOMAIN PROTEIN VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; VACCINE; CANCER VACCINE;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; OVARY CANCER; PRIORITY JOURNAL; TOXICITY; VACCINATION; ADULT; AGED; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; IMMUNOLOGY; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; BREAST NEOPLASMS; CANCER VACCINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2;

EID: 3042745485     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.09.005     Document Type: Article

References (27)

1. Disis ML, Knutson KL, Schiffman K, et al: Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 62:245-252, 2000
2. Scardino A, Gross DA, Alves P, et al: HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900-5906, 2002
3. Bremers AJ, Andreola S, Leo E, et al: T cell responses in colorectal cancer patients: Evidence for class II HLA-restricted recognition of shared tumor-associated antigens. Int J Cancer 88:956-961, 2000
4. Disis ML, Pupa SM, Gralow JR, et al: High titer HER-2/neu protein specific antibody immunity can be detected in patients with early stage breast cancer. J Clin Oncol 15:3363-3367, 1997
5. Foy TM, Bannink J, Sutherland RA, et al: Vaccination with Her-2/neu DMA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor. Vaccine 19:2598-2606, 2001
6. Knutson KL, Disis ML: Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER-2/neu peptide-based vaccine. Clin Breast Cancer 2:73-79, 2001
7. Zaks TZ, Rosenberg SA: Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 58:4902-4908, 1998
8. Knutson KL, Schiffman K, Disis ML: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CDS T-cell immunity in cancer patients. J Clin Invest 107:477-484, 2001
9. Disis ML, Gooley TA, Rinn K, et al: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20:2624-2632, 2002
10. Disis ML, Knutson KL, McNeel DG, et al: Clinical translation of peptide-based vaccine trials: The HER-2/neu model. Crit Rev Immunol 21:263-273, 2001
11. Knutson KL, Schiffman K, Cheever MA, et al: Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 8:1014-1018, 2002
12. Disis ML, Grabstein KH, Sleath PR, et al: Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 5:1289-1297, 1999
13. Finn OJ: Cancer vaccines: Between the idea and the reality. Nat Rev Immunol 3:630-641, 2003
14. Ward RL, Hawkins NJ, Coomber D, et al: Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Hum Immunol 60:510-515, 1999
15. Disis ML, Calenoff E, McLaughlin G, et al: Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16-20, 1994
16. Goldblatt D, Vaz AR, Miller E: Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzas type b conjugate vaccines following infant immunization. J Infect Dis 177:1112-1115, 1998
17. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999
18. Disis ML, Gralow JR, Bernhard H, et al: Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein. J Immunol 156:3151-3158, 1996
19. Bernards R, Destree A, McKenzie S, et al: Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci U S A 84:6854-6858, 1987
20. Casal J, Tarrago D: Immunity to Streptococcus pneumoniae: Factors affecting production and efficacy. Curr Opin Infect Dis 16:219-224, 2003
21. Reilly RT, Machiels JP, Emens LA, et al: The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 61:880-883, 2001
22. Martina BE, van de Bildt MW, Kuiken T, et al: Immunogenicity and efficacy of recombinant subunit vaccines against phocid herpesvirus type 1. Vaccine 21:2433-2440, 2003
23. de Jong A, O'Neill T, Khan AY, et al: Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TACIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20:3456-3464, 2002
24. Ehrlich HJ, Pavlova BG, Fritsch S, et al: Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: Evaluation of safety and immunogenicity. Vaccine 22: 217-223, 2003
25. Kundig TM, Bachmann MF, Oehen S, et al: On the role of antigen in maintaining cytotoxic T-cell memory. Proc Natl Acad Sci U S A 93: 9716-9723, 1996
26. Brossart P, Wirths S, Stuhler G, et al: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102-3108, 2000
27. Disis M, Shiota F, McNeel D, et al: Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self-tumor antigens. Immunobiology 207:179-186, 2003